Artelo Enters Second Collaboration With Trinity College Dublin For...

Pharma Tech Outlook: Pharma Tech Magazine

Artelo Enters Second Collaboration With Trinity College Dublin For Tumor Treatments

Pharma Tech Outlook | Friday, April 15, 2022

Artelo and Trinity College Dublin are expanding their collaboration to study the cell biology of Fatty Acid Binding Protein (FABP) inhibition in cancer.

Fremont, CA: “The potential role and implications of FABP inhibition in different forms of cancer is emerging as a very exciting and promising advancement in cancer research,” states Professor Porter. “This collaboration with Artelo will further elucidate the specific mechanisms by which targeted FABP inhibition may prevent tumor growth and halt its spreading.” Artelo Bioscience, a clinical-stage pharmaceutical business focusing on regulating lipid signaling pathways in order to develop medicines for patients living with cancer, pain, and neurological diseases, has entered into a second collaboration with Richard K. Porter, Ph.D., of Trinity College Dublin's School of Biochemistry & Immunology.

Professor Porter will be looking into the molecular reasons why fatty acid binding protein (FABP) inhibition can cause cancer and how the ART26.12 platform could be used to treat different types of tumors. Artelo thinks that the Trinity College research project will help the company better understand the role of certain FABP inhibitors and could lead to a lot of different drugs for different types of cancer from the Artelos library of drugs.

“FABP plays an important role in lipid signaling and is believed to be an attractive target for cancer drug development. Large amounts of human biomarker and animal model data support FABP as an oncology target. We believe the evidence to date suggests inhibition of FABP may be relevant in a number of different cancers with high unmet need. We are pleased to be working on a second research project with Professor Porter, who has more than 30 years experience in metabolism and bioenergetics,” comments Andrew Yates, Ph.D., Artelo Biosciences Chief Science Officer. “The research is expected to have multiple data readouts over the next twelve months.”

Weekly Brief

Read Also